IRD SEC Filing News — Opus Genetics, Inc.

Latest SEC filings for Opus Genetics, Inc. (IRD) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs…
Sector: Healthcare Industry: Biotechnology Market Cap: $333.6M CIK: 1228627
20
Total Filings
0
Bullish Classifications
7
Bearish Classifications
9
Insider Transactions
5
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for IRD currently lean bearish. Of the 20 filing records displayed, 7 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
IRD Filing Activity Snapshot 2026-05-20 — 2026-10-02
Insider Transactions (Form 4)
0 buys vs 7 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$7.39M
Foundation Fighting Blindness Retinal Degeneration Fund (Director) · 2026-05-20
1,700,000 shares · Form 4
Form 144 Notices
5
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Opus Genetics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 7 open-market sale and 2 option exercise. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×7
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×2
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Open-market sale Insider Selling 2026-10-02

IRD insider Foundation Fighting Blindness Retinal Degeneration Fund (Director) sold 556,000 shares (~$2.76M)

Foundation Fighting Blindness Retinal Degeneration Fund, listed as Director at Opus Genetics, Inc., reported an open-market sale of 556,000 IRD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 556,000 $4.96 $2.76M
Filing: Form 4 (Insider Transaction) Insider: Foundation Fighting Blindness Retinal Degeneration Fund (Director) Shares: 556,000 Est. Value: $2.76M
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-11

IRD insider Form 4 filed for equity award, exercise, or tax withholding

Magrath George (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 392,157 $1.15 $451.0K
F Tax withholding on vested shares 75,541 $5.97 $451.0K
M Option exercise derivative · Warrant (right to buy) 392,157 — —
Filing: Form 4 (Insider Transaction) Insider: Magrath George (Director, Chief Executive Officer) Shares: 467,698
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-08

IRD insider Form 4 filed for equity award, exercise, or tax withholding

Gallagher Cam (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 784,314 $1.15 $902.0K
M Option exercise derivative · Warrant (right to buy) 784,314 — —
Filing: Form 4 (Insider Transaction) Insider: Gallagher Cam (Director) Shares: 784,314
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-08

IRD insider Gagnon Robert E. (Chief Financial Officer) sold 28,000 shares (~$127.2K)

Gagnon Robert E., listed as Chief Financial Officer at Opus Genetics, Inc., reported an open-market sale of 28,000 IRD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 28,000 $4.54 $127.2K
Filing: Form 4 (Insider Transaction) Insider: Gagnon Robert E. (Chief Financial Officer) Shares: 28,000 Est. Value: $127.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-27

IRD insider YERXA BENJAMIN R (Director, President) sold 7,429 shares (~$22.1K)

YERXA BENJAMIN R, listed as Director, President at Opus Genetics, Inc., reported an open-market sale of 7,429 IRD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 7,429 $2.97 $22.1K
Filing: Form 4 (Insider Transaction) Insider: YERXA BENJAMIN R (Director, President) Shares: 7,429 Est. Value: $22.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-27

IRD insider SCHACHLE JOSEPH K (Chief Operating Officer) sold 4,644 shares (~$13.7K)

SCHACHLE JOSEPH K, listed as Chief Operating Officer at Opus Genetics, Inc., reported an open-market sale of 4,644 IRD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 4,644 $2.94 $13.7K
Filing: Form 4 (Insider Transaction) Insider: SCHACHLE JOSEPH K (Chief Operating Officer) Shares: 4,644 Est. Value: $13.7K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-27

IRD insider Magrath George (Director, Chief Executive Officer) sold 9,475 shares (~$27.9K)

Magrath George, listed as Director, Chief Executive Officer at Opus Genetics, Inc., reported an open-market sale of 9,475 IRD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 9,475 $2.95 $27.9K
Filing: Form 4 (Insider Transaction) Insider: Magrath George (Director, Chief Executive Officer) Shares: 9,475 Est. Value: $27.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-27

IRD insider Gagnon Robert E. (Chief Financial Officer) sold 7,783 shares (~$22.9K)

Gagnon Robert E., listed as Chief Financial Officer at Opus Genetics, Inc., reported an open-market sale of 7,783 IRD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 7,783 $2.95 $22.9K
Filing: Form 4 (Insider Transaction) Insider: Gagnon Robert E. (Chief Financial Officer) Shares: 7,783 Est. Value: $22.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-20

IRD insider Foundation Fighting Blindness Retinal Degeneration Fund (Director) sold 1,700,000 shares (~$7.39M)

Foundation Fighting Blindness Retinal Degeneration Fund, listed as Director at Opus Genetics, Inc., reported an open-market sale of 1,700,000 IRD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,700,000 $4.35 $7.39M
Filing: Form 4 (Insider Transaction) Insider: Foundation Fighting Blindness Retinal Degeneration Fund (Director) Shares: 1,700,000 Est. Value: $7.39M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Opus Genetics, Inc. has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-03

IRD Form 144 filed for proposed insider sale by Gagnon Robert E. (28,000 shares) ~$124.6K

Gagnon Robert E. filed a Form 144 with the SEC indicating intent to sell IRD (Opus Genetics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Gagnon Robert E. Shares: 28,000 Est. Value: $124.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-23

IRD Form 144 filed for proposed insider sale by Gagnon Robert E. (7,783 shares) ~$23.7K

Gagnon Robert E. filed a Form 144 with the SEC indicating intent to sell IRD (Opus Genetics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Gagnon Robert E. Shares: 7,783 Est. Value: $23.7K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-23

IRD Form 144 filed for proposed insider sale by Magrath George (9,475 shares) ~$28.9K

Magrath George filed a Form 144 with the SEC indicating intent to sell IRD (Opus Genetics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Magrath George Shares: 9,475 Est. Value: $28.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-23

IRD Form 144 filed for proposed insider sale by SCHACHLE JOSEPH K (4,644 shares) ~$13.7K

SCHACHLE JOSEPH K filed a Form 144 with the SEC indicating intent to sell IRD (Opus Genetics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SCHACHLE JOSEPH K Shares: 4,644 Est. Value: $13.7K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-23

IRD Form 144 filed for proposed insider sale by YERXA BENJAMIN R (7,429 shares) ~$22.1K

YERXA BENJAMIN R filed a Form 144 with the SEC indicating intent to sell IRD (Opus Genetics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: YERXA BENJAMIN R Shares: 7,429 Est. Value: $22.1K
View on SEC EDGAR → Open Filing Document →
Material Events 5 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 5 in this period for Opus Genetics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-11

IRD filed 8-K — material company event

Opus Genetics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-09

IRD filed 8-K — material company event

Opus Genetics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-06

IRD filed 8-K — material company event

Opus Genetics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-16

IRD filed 8-K — material company event

Opus Genetics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-16

IRD filed 8-K — material company event

Opus Genetics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Opus Genetics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

IRD filed Quarterly Report (10-Q)

Opus Genetics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Opus Genetics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on IRD. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — IRD SEC Filings

More Tools for IRD

IRD Full Stock Analysis IRD Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper IRD analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the IRD stock analysis page.

IRD Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer